57th ASH Annual Meeting and Exposition (December 5-8, 2015): 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutics and the Impact of the Microenvironment

Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy Oral and Poster Abstracts
Oral

W414AB, Level 4 (Orange County Convention Center)

Moderators:

Lawrence H. Boise, PhD, Emory University and Giovanni Tonon, MD, PhD, Ospedale San Raffaele

Disclosures:

No relevant conflicts of interest to declare.

2:00 PM

CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets

Sophia Danhof, MD¹^*, Tea Gogishvili, PhD¹^*, Silvia Koch¹^*, Martin Schreder, MD¹^*, Stefan Knop²^*, Hermann Einsele³ and Michael Hudecek, MD¹^*

¹Department of Internal Medicine II, Division of Hematology and Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, Germany
²Department of Internal Medicine. II, Wuerzburg, Germany
³2Department of Internal Medicine. II, Wuerzburg, Germany

2:15 PM

116

Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)

Roman Galetto, PhD^*, Isabelle Chion-Sotinel^*, Agnès Gouble, PhD^* and Julianne Smith, Ph.D

Cellectis SA, Paris, France

2:30 PM

117

Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma

Anja Seckinger, MD¹^*, Jose Antonio Delgado²^*, Laura Moreno²^*, Brigitte Neuber, PhD¹^*, Anna Grab, PhD¹^*, Susanne Lipp, MS¹^*, Juana Merino, MD PhD²^*, Minh Diem Vu, PhD³^*, Klaus Strein, MD, PhD³^*, Felipe Prosper, MD PhD⁴^*, Michael Hundemer, MD⁵^*, Jesus San Miguel, MD PhD²^*, Dirk Hose, MD¹ and Bruno Paiva, PhD²^*

¹Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany
²Department of Hematology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain
³EngMab AG, Wilen, Switzerland
⁴Department of Hematology and Immunology, CIMA/UNAV/IDISNA, Pamplona, Spain
⁵Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

2:45 PM

118

A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

Damian J Green, MD¹, Jon C Jones²^*, Yukang Lin²^*, Shani L. Frayo³^*, Aimee L Kenoyer, BS²^*, Shyril O'Steen²^*, Arianna Peters³^*, Sofia HL Frost, PhD²^*, Johnnie J. Orozco, MD, PhD⁴, Ajay K Gopal, MD³, Mark D Hylarides, PhD²^*, Darrell R Fisher, PhD⁵^*, Brenda M. Sandmaier, MD^4,6, Brian G. Till, MD¹, Ethan R Balkin, PhD⁷^*, Don K Hamlin⁷^*, D.Scott Wilbur, PhD⁷^*, Kelly D Orcutt, PhD⁸^*, K. Dane Wittrup, PhD⁸^* and Oliver W. Press, MD, PhD^4,9

¹Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
²FHCRC, Seattle, WA
³Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁵Dade Moeller Health Group, Richland, WA
⁶Division of Medical Oncology, University of Washington, Seattle, WA
⁷Department of Radiation Oncology, University of Washington, Seattle, WA
⁸Massachusetts Institute of Technology, Boston, MA
⁹University of Washington, Seattle, WA

3:00 PM

119

Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden

Michaela R. Reagan, PhD^1,2, Michelle McDonald, PhD³^*, Rachael Terry, PhD³^*, Jessica Pettitt³^*, Lawrence Le³^*, Sindhu Mohanty, PhD³^*, Michaela Kneissel, PhD⁴^*, Ina Kramer, PhD⁴^*, Daniel Brooks⁵^*, Mary Bouxsein, PhD⁵^*, Clifford J. Rosen, MD¹^*, Irene M. Ghobrial, MD⁶ and Peter Croucher, BSc, PhD³^*

¹Maine Medical Center Research Institute, Scarborough, ME
²Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
³Garvan Institute of Medical Research, Sydney, Australia
⁴Novartis Institutes for BioMedical Research, Basel, Switzerland
⁵Beth Israel Deaconess Medical Center, Boston, MA
⁶Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

3:15 PM

120

Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice

Rituparna Das, PhD¹^*, Till Strowig, PhD²^*, Rakesh Verma, Ph.D³, Srinivas Koduru, PhD¹^*, Anja Hafemann, PhD²^*, Stephanie Hopf²^*, Mehmet H. Kocoglu, MD⁴, Chiara Borsotti, PhD⁵^*, Lin Zhang¹^*, Andrew R Branagan, MD³, Elizabeth Eynon, PhD²^*, Markus Manz, MD⁵, Richard Flavell, Ph.D²^* and Madhav V Dhodapkar, MD⁶

¹Yale Cancer Center, New Haven, CT
²Department of Immunobiology, Yale School of Medicine, New Haven, CT
³Department of Medicine, Yale Cancer Center, New Haven, CT
⁴Department of Medicine and Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD
⁵Department of Hematology, University Hospital Zurich, Zurich, Switzerland
⁶Department of Medicine / Hematology Section, Yale University School of Medicine, New Haven, CT

See more of: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O1.6 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutics and the Impact of the Microenvironment